Stay updated with breaking news from Dror Bashan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good morning ladies and gentlemen and welcome to the Protalix full year 2022 earnings call. As a reminder, this conference is being recorded.
A PEGylated enzyme replacement therapy for Fabry disease has received a positive opinion from the EMA's human medicines committee.
/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
Treatments for blood cancer and rare diseases are the target markets, but investors are well aware of the challenges that await after approval is received.